Citius Pharmaceuticals, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities The information regarding our equity compensation plans required by this Item is found in Item 12 of this report. Market Information Our common stock and certain warrants to purchase common stock trade on The Nasdaq Capital Market under the symbol “CTXR” and “CTXRW,” respectively. Holders of Common Stock As November 30, 2021, we had approximately 96 stockholders of record of our common stock. Dividends We have never paid dividends on our common stock. We intend to follow a policy of retaining earnings, if any, to finance the growth of our business and do not anticipate paying any cash dividends in the foreseeable future. The declaration and payment of future dividends on the common stock will be at sole discretion of our Board of Directors and will depend on our profitability and financial condition, capital requirements, statutory and contractual restrictions, future prospects and other factors deemed relevant by the Board. Recent Sales of Unregistered Securities None. Issuer Purchases of Equity Securities We did not make any purchases of our common stock during the three months ended September 30, 2021, which is the fourth quarter of our fiscal year. Item 6. [Reserved]